April 10, 2013 - A new paper from the West lab and collaborators is published that demonstrates the usage and capabilities of the next generation of antibodies that target LRRK2. This work will help researchers understand the role of LRRK2 in Parkinson’s disease. This project was jointly directed by Dr. West and Dr. Heather Melrose at the Mayo Clinic.
April 7, 2013 - An active collaboration with the Central Alabama High Field NMR Facility was formed, using one of the most powerful NMRs in the country, the 850 MHz Bruker Avance III NMR Spectrometer (Ascend) with a CryoProbe, to understand LRRK2 protein structure in Parkinson’s disease. These studies will allow the optimization of the most effective drugs that target LRRK2 for the possible preventation and treatment of Parkinson’s disease.
March 8, 2013 - The Alabama Drug Discovery Alliance and SRI have converted the first of possibly many patents on LRRK2 small molecule inhibitors to full protection status! This will allow expediting these drugs to clinical trials in Parkinson’s disease.
February 3, 2013 - The West lab, working together with the UAB Movement disorder center, has deposited some of the first samples to the brand new Parkinson’s Disease Biomarkers Program! NIH has prioritized the creation of this database to figure out the causes and cures for Parkinson’s disease, and UAB will be one of the leading contributor of samples, working together with PD-affected individuals and their care-takers in the southeastern United States. If you would like to participate in this program and are able to travel to Birmingham, please email Rachel Clark, R.N., at email@example.com. Your help is needed to defeat PD!
January 2, 2013 - Laura Volpicelli-Daley, an accomplished researcher with a track record of major findings in neurodegeneration, joins the West lab and Department of Neurology as a faculty Instructor to help solve the biochemical causes of Parkinson’s disease. The West lab welcomes Laura to the team!